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Abstract
Background—A proportion of subjects with symptoms of posttraumatic stress disorder (PTSD)
are unresponsive to specialized psychotherapy, but a biological basis for this has not been described.
To observe whether differences in cortisol or its metabolites predict or correlate with response to
therapy for PTSD symptoms, cortisol and its metabolites were measured from urine samples at pre-
treatment, at the conclusion of psychotherapy, and at 3-month follow-up.
Methods—28 survivors of the World Trade Center attack on September 11, 2001 seeking
psychological treatment for PTSD symptoms received four sessions of either exposure therapy or
supportive counseling, followed by up to 10 sessions of prolonged exposure in a specialized PTSD
treatment program at a private hospital serving the New York City metropolitan area. 24-hr mean
integrated cortisol excretion was assessed by radioimmunoassay (RIA); urinary free cortisol and
metabolites cortisone, 5α–tetrahydrocortisol (5α-THF), 5β–tetrahydrocortisol, and
tetrahydrocortisone were assessed by gas chromatography-mass spectrometry (GCMS); and indices
of enzyme activities for 5α–and 5β–reductase and for the 11β–hydroxysteroid dehydrogenases were
derived from the metabolite and glucocorticoid measures.
Results—5α-reductase activity was significantly lower at pre-treatment among non-responders,
whereas there were no significant pre-treatment differences between responders and non-responders
in any other hormone or metabolite level. In repeated-measures analyses across the three time points,
Correspondence: Rachel Yehuda, Ph.D., Psychiatry OOMH, Bronx Veteran Affairs Medical Center, 130 West Kingsbridge Road, Bronx,
NY 10468., rachel.yehuda@va.gov, Telephone: 1 (718) 584-9000 ext. 6964, Fax: 1 (718) 741-4775.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
CONTRIBUTORS
Authors Rachel Yehuda, Ph.D. and Linda M. Bierer, M.D. designed the study and wrote the protocol, oversaw data management,
collection and analysis and prepared the manuscript. Author Casey Sarapas managed the literature searches, compiled references and
composed tables and figures. Author Iouri Makotkine, M.D. was responsible for lab standardization, ensured quality control of biological
specimen collection, processing and shipping, and performed urine extraction and cortisol radioimmunoassay. Author Ruth Andrew,
Ph.D. performed metabolite assays on GCMS, which was overseen by author Jonathan R. Seckel, M.D., Ph.D. Authors Andrew and
Seckel interpreted biological data, performed data analysis and assistant in manuscript preparation.
All authors had full access to all of the data in the study, take responsibility for the integrity of the data and the accuracy of the data
analysis, and have approved the final manuscript.
NIH Public Access
Author Manuscript
Psychoneuroendocrinology. Author manuscript; available in PMC 2010 October 1.
Published in final edited form as:
Psychoneuroendocrinology. 2009 October ; 34(9): 1304–1313. doi:10.1016/j.psyneuen.2009.03.018.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
5α-reductase activity, as well as 5α-THF and total glucocorticoids, significantly differed between
responders and non-responders. For urinary cortisol measured by RIA, there was a significant group
× time interaction indicating that, although not different at pre-treatment, urinary cortisol levels
declined over time in the non-responder group, such that by follow-up, lowered cortisol significantly
distinguished non-responders from responders. Indices of 5α-reductase activity, including 5α-THF
and total glucocorticoids, were significantly negatively correlated with avoidance symptom severity
at pre-treatment. At follow-up, indices of 5α-reductase activity were significantly negatively
correlated with severity of all three PTSD symptom clusters and with total PTSD severity scores.
Conclusion—Lower 5α–reductase activity is associated with avoidance severity and predicts non-
responsiveness to psychological treatment for PTSD symptomatology. Relatively diminished 5α–
reductase activity may mark a state of primary vulnerability, perhaps via attenuated peripheral
catabolism of cortisol resulting in the suppression of hypothalamic-pituitary-adrenal axis
responsiveness. Lower cortisol levels appear later in the progression to chronic, treatment-resistant
PTSD.
Keywords
Posttraumatic stress disorder; cortisol; cortisol metabolites; glucocorticoid metabolism; biological
markers; psychotherapy; 5α-reductase; 5α-tetrahydrocortisol (5α-THF)
INTRODUCTION
Although psychotherapeutic interventions accelerate recovery from posttraumatic stress
disorder (PTSD), a proportion treated fail to show substantial reduction of symptoms or
remission (Ehlers et al., 2003; Sijbrandij et al, 2007; Bryant et al., 2008). To date, however,
few psychological (Forbes et al., 2002, 2003a, 2003b) or biological indices (Olff et al., 2007)
have been shown to predict or correlate with treatment outcome. Cortisol is associated with
normative adaptations to stress. Lower than normal basal cortisol levels have been consistently
reported in chronic (>3 months after trauma) PTSD in combat veterans (Mason et al, 1986;
Boscarino, 1996; Yehuda et al., 1996), Holocaust survivors (Yehuda et al., 1995; 2007a),
victims of chronic child abuse or domestic violence (King et al., 2001; Griffin et al., 2005;
Bremner et al., 2007), but are more variable in association with single-incident civilian
traumatization (Yehuda, 2006). Furthermore, findings of low cortisol may vary based on
sampling methodology (e.g., single plasma or serum samples vs. integrated urine collections),
collection times, or participant characteristics (e.g., gender) (Meewisse et al., 2007).
Lower cortisol levels may be a vulnerability trait for PTSD, a notion supported by observations
of lower cortisol levels in those “at risk” for PTSD, such as offspring of persons with PTSD
(Yehuda et al., 2005a; 2007b). Additionally, low cortisol levels have been reported early after
acute trauma in some studies (Yehuda et al., 2005b; Delahanty & Nugent, 2006). However,
cortisol levels may show posttraumatic accommodations in those who develop PTSD, as
evidenced by a failure to observe consistent reductions several weeks or months following
trauma exposure (Hawk et al., 2000; Bonne et al., 2003; Shalev et al., 2008). To date, there
has been only one longitudinal study of biological alterations in association with a
psychotherapeutic intervention for PTSD (Olff et al., 2007), in addition to a single case report
(Kellner et al., 2002).
To address the paucity of longitudinal data on biological alterations in PTSD, we assessed
glucocorticoids in 24-hr urine samples in trauma survivors seeking treatment for PTSD and
related symptoms in the months following the World Trade Center (WTC) attack on September
11, 2001. Samples were evaluated prior to treatment onset, at the conclusion of psychotherapy,
and at three month follow-up. In addition to evaluating urinary cortisol using standard
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radioimmunoassay (RIA) procedures, gas chromatography-mass spectrometry (GCMS) was
used to estimate urinary-free cortisol (F) as well as the concentration of inactive glucocorticoid
metabolites including cortisone (E), 5α-tetrahydrocortisol (5α–THF), 5β-tetrahydrocortisol
(5β-THF), and tetrahydrocortisone (THE). Quantification of these metabolites allows
inferences to be made regarding the activity of enzymes involved in glucocorticoid metabolism
by calculating the ratios of respective glucocorticoid metabolites to cortisol.
Specifically, we examined whether changes in 11β-hydroxysteroid dehydrogenases (11β-
HSDs) and 5α- and 5β-reductases were associated with acute and chronic neuroendocrine and
symptomatic parameters of PTSD (Seckl, 2008). The two isozymes of 11β-HSD catalyze
interconversion of active cortisol and inert cortisone (Seckl and Walker, 2001). 11β-HSD
type-1 reduces inert E to active F in liver, fat and brain, resulting in greater intracellular free
cortisol (Paterson et al., 2004). Reciprocally, 11β-HSD type-2 rapidly inactivates F to E in
distal nephron (Edwards et al., 1998). Cortisol is also catabolized largely in the liver by 5α-
and 5β-reductases (Westerbacka et al., 2003). Variation in these enzymes impacts upon cortisol
half-life and thus hypothalamic-pituitary-adrenal (HPA) axis activity (Westerbacka et al.,
2003). We hypothesized that cortisol and its metabolism, at least some of which is determined
by genetics (Hebbar and Archer, 2007) and early life events (Seckl and Meaney, 2006;
Oberlander at al., 2008), would predict and parallel symptomatic recovery in PTSD.
Specifically, we predicted that low cortisol levels would be associated with PTSD symptom
severity, and would be significantly lower post-treatment in non-responders. Despite these
directional hypotheses for cortisol, two-tailed significance tests were used in all analyses.
METHODS
Participants
Participants were 28 survivors of the terrorist attack on the WTC in New York City who
responded to advertisements for a psychological treatment study, and were drawn from a larger
study aimed at investigating the efficacy of a brief course (4 sessions) of prolonged exposure
therapy (PE) compared to supportive counseling (SC). After four weeks, participants who did
not achieve substantial recovery were offered up to 10 additional sessions of PE. 51 participants
began treatment in the larger study; of these, 44 completed the trial (defined as receiving at
least four initial sessions, plus additional sessions if responder status had not been achieved
following the fourth session). Since the collection of biological samples was optional, only 28
of the 44 completers provided a post-treatment urine sample. These 28 participants comprise
the sample included in this study, of whom 14 had initially been randomized to PE and 14 to
SC. A brief report describing urinary cortisol and norepinephrine levels at the initial evaluation
was published elsewhere (Bierer, et al., 2006).
Recruitment was initiated within three months of 9/11, and closed approximately one year
later. Mean duration (±SD) from 9/11 to pre-treatment evaluation was 283±106 days.
Participants were included if they were 18 years or older, reported re-experiencing symptoms
and distress related to the WTC attack, and did not meet exclusion criteria. Exclusion criteria
were the presence of an Axis I disorder other than PTSD, major depressive disorder (MDD),
or anxiety disorder; evidence of current suicidal intent or behavior (3 or 4 on the suicide item
of the Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) or otherwise assessed as a
suicide risk); indication of alcohol or illicit drug abuse or dependence within three months of
study; and unwillingness to suspend current psychotherapy. Participants who had been taking
stable doses of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine
reuptake inhibitors (SNRIs) for three or more months (n=9) were not asked to withdraw from
medication use, but those using these medications for less than three months, ingesting other
psychotropic medications, or ingesting medications that might interfere with the assessment
of the HPA axis (e.g., steroids, beta-blockers, indomethacin) were not included. Prior to
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treatment initiation, 3 were excluded due to substance abuse or dependence; 2 due to medication
exclusions; 2 did not meet the minimum PTSD severity score for inclusion; 2 had excluded
psychiatric diagnoses; 1 due to a medical exclusion; and 1 due to having a focal trauma other
than 9/11 (and was treated in our clinic but not included for research). After treatment initiation,
2 were discovered to be ineligible (one due to a lapse in alcohol abstinence, and one as it became
apparent that symptoms were in response to a trauma prior to 9/11). All subjects signed
informed consent for treatment participation, which was offered at no cost; subjects were
reimbursed for providing biological samples. The study protocol was reviewed and approved
by the institutional review board at the Mount Sinai School of Medicine.
Study design
An independent evaluation was conducted by a clinical psychologist in order to determine
eligibility for the study and to confirm diagnostic status. The Posttraumatic Stress Symptom
Scale-Interview (PSS-I) measured the presence and severity of PTSD (Foa et al., 1993). Other
psychiatric diagnoses were made using the Structured Clinical Interview for the DSM-IV-TR
(SCID; Spitzer et al., 1995). The HDRS was administered to assess suicidality and severity of
depressive symptoms. Participants also completed the PTSD Symptom Scale-Self Report
(PSS-SR) to assess severity of PTSD (Foa et al., 1997). Subjects were advised to schedule
urine collections during a 24-hr period anticipated to be relatively quiescent, in order to obtain
estimates of ‘basal’ glucocorticoid production. Collections for female subjects were scheduled
during the follicular phase of the menstrual cycle (Symonds et al., 2004). Participants were
evaluated by a non-treating (independent) psychologist at the completion of therapy, and again
after a three-month naturalistic follow-up.
Biological measures
Cortisol and its metabolites were measured in batched assays by electron impact GCMS as
previously described (Best and Walker, 1997). The limit of sensitivity for the glucocorticoid
measures is 2ng: no interferences were observed. Interassay coefficients of variations were
<10% for cortisol and metabolites. Figure 1 provides a summary of the biosynthetic pathways
related to cortisol metabolism measured in the current study. Total glucocorticoids were
calculated as the sum of F and its metabolites E, 5α-THF, 5β-THF, and THE. 5α-reductase
activity was inferred from the ratio of 5α-THF/ F, and 5β-reductase activity, similarly from the
ratio of 5β-THF/ F. 11β-HSD-2 activity was inferred from the ratio of E/ F; total 11β-HSD
activity from the ratio (5α-THF + 5β-THF)/THE (Palermo et al., 1996). To provide an index
of completeness of collection, creatinine concentrations were measured and urine volumes
were reviewed. We measured urinary-free cortisol derived from RIA since this measure is often
used in the literature. RIA measures of cortisol provide an estimate of total adrenal output, but
the antibody used in the procedure can cross-react with cortisol metabolites, and may not
provide information about bioactive cortisol levels, (F), as measured by GCMS (Yehuda,
2002).
Statistical methods
The basic statistical method consisted of a comparison between two groups: those who
demonstrated substantial recovery (defined by a score of 10 or less on the PSS-I and no longer
meeting diagnostic criteria for PTSD), and those who did not. The psychological ratings and
urinary RIA measures of cortisol did not have distributions that were substantially kurtotic.
GCMS data were log transformed for all analyses (other than descriptions of percent change),
but means and estimated standard errors of means based on pooled groups, and graphics in all
cases are based on raw data for descriptive purposes. There were no significant associations
between biological measures and age, gender, body mass index (BMI), medication status,
presence of comorbid depression, and days since 9/11 at pre-treatment; however, BMI, gender,
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and age showed some associations with GCMS measures at subsequent time points and were
therefore used as covariates in all analyses of F, glucocorticoid metabolites and enzyme indices.
Repeated measures analysis of covariance (ANCOVA) for pre-treatment, post-treatment and
follow-up assessments was used as the principal method of group comparison to assess
differences linear trends for biological measures. Bonferroni criteria were applied to urinary
cortisol and its metabolites (5 measures) separately from enzyme indices (4 measures) as the
latter were derived from the former and therefore were essentially redundant. To identify
potential biological predictors and correlates of treatment response, respectively, measures
meeting Bonferroni criteria for significance from the repeated measures analyses were further
evaluated by ANCOVA at pre-treatment, and subjected to partial correlation analyses with
symptom severity measures at pre- and post-treatment and at follow-up.
RESULTS
Differences in Demographic and Clinical Characteristics at Pre-treatment
At pre-treatment evaluation (Table 1), PTSD subjects who would subsequently not respond to
therapy (non-responders) were significantly older and had a higher BMI than those who would
demonstrate a criterion treatment response (responders), but there were no differences in
gender or prior trauma exposure. However, after controlling for age, the two groups no longer
differed significantly on BMI (F=3.14, df=1,25, ns). For the majority of participants in either
group, 9/11 was deemed their worst lifetime traumatic event. There were also no differences
in rates of current depression diagnoses, other anxiety disorders, or past substance abuse. Total
PTSD and depression severity scores as assessed by clinician ratings were similarly comparable
for responders and non-responders at pre-treatment.
At the time of post treatment evaluation, however, there were significant group differences
between responders and non-responders in clinician ratings for both PTSD and depression (for
PTSD: F=17.69, df=1,26, p<.0005; for HDRS scores: F=7.98, df=1,26, p=.010) that were
sustained at follow-up (for PTSD: F=37.96, df=1,36, p<.0005; for HDRS scores: F=8.56,
df=1,26, p=007). Table 2 demonstrates significant effects of time, indicating that improvement
occurred in both the responder and non-responder groups; the significant group × time
interactions indicate that the responders showed significantly greater improvements than did
the non-responders (by definition); with the significant group effects for PTSD and depression
ratings indicating that, averaged across the three time points, these differences were substantial.
Treatment effects on biological measures
Repeated measures ANCOVA showed significant group effects for 5α-THF and for total
glucocorticoids, which reflects primarily the contribution of 5α-THF. To illustrate the
significant contribution of 5α-THF to the level of total glucocorticoids, urinary levels of these
metabolites are highly correlated at pre-treatment (partial r=.904, df=23, p<.0005), and almost
as highly correlated at post-treatment and follow-up (at both time points, partial r=.873, df=23,
p<.0005). These findings indicate a persistent effect of diminished 5α-reduction in the non-
responders. Similar, but weaker results were found for 5β-THF and THE, indicating lower
5β-reduction among the non-responders, but these results did not meet Bonferroni criteria. The
findings pertaining to diminished 5α-reduction among non-responders is borne out entirely by
repeated measures analyses of the enzyme indices. A significant group effect is noted for 5α-
reductase, indicating reduced activity in the non-responders that satisfies Bonferroni
considerations, whereas a similar but weaker finding for the 5β-reductase index does not.
Neither of the 11β-HSD enzymes (total or 11β-HSD-2) appeared to be altered by trauma
focused treatment. Among the glucocorticoids, metabolites and enzyme indices derived from
GCMS determinations, there were no significant effects of time, and no significant group ×
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time interactions. These findings were not substantially altered by re-analysis with additional
covariation for depression and/or medication status.
Differences in biological measures at pre-treatment
In order to identify predictors of recovery, we next employed univariate ANCOVA to compare
pre-treatment values for responders and non-responders for the three biological measures for
which a significant effect was found in the repeated measures analyses. Thus, Bonferroni
corrections were applied to two metabolite measures (5α-THF and total glucocorticoids, each
at α<.025) and to one enzyme index (5α-reductase, α<.05). 5α-reductase activity was identified
as a predictor of treatment response. Non-responders demonstrated significantly reduced 5α-
reductase activity (F=6.43, df=23, p=.019) in comparison to responders (there was greater than
70% lower pre-treatment 5α-reductase activity among non-responders). However, neither pre-
treatment levels of 5α-THF (F=0.15, df=23, ns) or total glucocorticoids (F=1.01, df=23, ns)
distinguished responders from non-responders.
For descriptive purposes, pre-treatment levels of F, glucocorticoid metabolites other than 5α-
THF and enzymes other than 5α-reductase were compared for non-responders and responders,
controlling for age, gender and BMI. There were no significant differences between the
treatment responder groups in any of these measures, or in pre-treatment level of RIA-
cortisol. .These findings, like those of the repeated measures ANCOVAs, were not
substantively altered by additional covariation for depression or medication status.
Findings for RIA Cortisol
The primary outcomes of the present study were F, its metabolites, and glucocorticoid
metabolic enzyme indices, as determined by estimating ratios of metabolites assessed by
GCMS. Cortisol levels were also assessed by RIA, principally to facilitate comparison of the
present results to previous findings pertaining to glucocorticoids in PTSD. At pre-treatment,
urinary cortisol measured by RIA was significantly correlated with F (r=.694, df=23, p<.0005)
and total glucocorticoids (r=.697, df=23, p<.0005), as well as each of the other glucocorticoid
metabolites; for instance, RIA-cortisol was almost as strongly correlated with 5α-THF (r=.637,
df=23, p=.001), and similarly correlated with 5β-THF (r=.691, df=23, p<.0005), as with F.
Repeated measures ANCOVA indicated a significant group × time interaction for urinary RIA
cortisol (F=11.6, df=1,26, p=.002) in the absence of a main effect of group or time. Though
not different at pre-treatment (mean± SE, non-responders: 51.9 ± 5.5; responders: 49.1 ± 5.5),
RIA cortisol levels declined appreciably over time in the non-responder group and increased
(less dramatically) in the responder group, such that by the follow-up assessment, the two
groups were significantly distinguishable (mean± SE, non-responders: 37.5 ± 5.3; responders:
55.0 ± 5.3).
Relationship of glucocorticoid production to treatment response
Examination of the descriptive data provided in Table 2 reveals a consistent overall pattern:
glucocorticoid metabolites trend downward among non-responders from pre-treatment to post-
treatment, and appear to stabilize or continue to decline from post-treatment to follow-up. This
treatment effect is not observed in the enzyme data, where, fundamentally, stable indices are
observed overtime, and group differences do not emerge, but are generally apparent at pre-
treatment and persist across the three assessments.
The pattern observed for the metabolite data is summarized graphically in Figure 2, which
illustrates that the predominant effect overtime for the non-responder group was to show a
decline in the production of cortisol and its metabolites, while those who responded to treatment
tended to increase production. The figure depicts percent change of group means from pre-
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treatment to follow-up in F, E, 5α–THF, 5β-THF and THE, for the non-responders and
responders, respectively. Calculated individually, percent change was negative for the non-
responders and positive for the responders in F and every metabolite other than 5α–THF in
which the percent increase among non-responders (35.0%) was only half as great as that for
the responders (97.1%), but this difference was not significant (F=.83, df=22, ns), controlling
for age, gender, BMI, and pre-treatment 5α–THF level. Percent change in total glucocorticoids,
however, differed significantly between non-responders (−17.0%) and responders (64.2%)
(F=5.05, df=22, p=.035), controlling for age, gender, BMI, and the level of total glucocorticoids
at pre-treatment.
Associations between biological and symptom measures at pre-treatment and over time
Only 5α–THF, and total glucocorticoids, which is highly reflective of the contribution of 5α–
THF, were shown to differentiate treatment responders from non-responders significantly in
the repeated measures analyses. Of the enzyme indices, only 5α-reductase significantly
differentiated these groups, but unlike the metabolites, the enzyme activity was significantly
reduced among the non-responders at pre-treatment. Each of these three biological measures
was evaluated for their association with PTSD symptom ratings at pre-treatment, and at follow-
up as indicated in Table 3. Prior to treatment, urinary 5α–THF was significantly negatively
associated with self-ratings for avoidance, as was total glucocorticoids, though somewhat less
so. Negative correlations for 5α–reductase measures with avoidance scores were of similar
magnitude prior to and following treatment. At follow-up, when a greater range was apparent
for behavioral as well as biological measures as a result of clinical improvements among
responders, significant correlations are evident for all three indices of 5α–reduction (5α–THF,
total glucocorticoids, and 5α–reductase) across the three behavioral dimensions of PTSD and
PTSD total score. All significant partial correlation results shown in Table 3 at pre-treatment
and at follow-up for measures of 5α–reduction meet Bonferroni criteria.
There were only few pre-treatment biological predictors of PTSD symptom severity at follow-
up, and all pertained to lower pre-treatment estimated 5α-reductase activity predicting greater
follow-up PTSD symptom severity (i.e., pre-treatment 5α-reductase activity with follow-up
self-rated intrusive symptoms, r=−.479, df=23, p=.018, and PTSD total score, r=−.407, df=23,
p=.044). Lower pre-treatment self-rated avoidance symptoms correlated negatively with RIA
cortisol at pre-treatment (r=−.500, df=23, p=.007) and at follow-up (r=−.550, df=23, p=.041).
For descriptive purposes, similar correlational analyses were evaluated for pre-treatment F,
metabolites other than 5α–THF, and enzymes other than 5α–reductase. None of these
glucocorticoids, metabolites, or enzyme indices was significantly associated with self- or
clinician rated PTSD symptom subscales or total score at pre-treatment or follow-up.
DISCUSSION
This study demonstrates differences in urinary cortisol parameters over time in treatment
seeking subjects who were deemed non-responders to psychotherapy for PTSD compared to
those who showed full recovery. The findings replicate and extend observations from the only
other longitudinal study of cortisol alterations in PTSD before and after cognitive behavioral
therapy (CBT), which demonstrated a further decrement in morning plasma cortisol levels
post-treatment in non-responders, while those who did respond showed cortisol increases
following CBT (Olff et al., 2007). Similar to the current study, plasma cortisol levels at pre-
treatment were not significantly different between responders and non-responders, nor did pre-
treatment cortisol levels predict treatment outcome. That cortisol levels might change in
association with symptom modification is consistent with observations of a relationship
between low cortisol levels and high PTSD symptom severity in chronic patients (Baker et al.,
1999; Goenjian et al., 2003; Olff et al., 2006a). Interestingly, cortisol levels changed most in
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this and the previous longitudinal study in those demonstrating the least change in clinical
symptoms, i.e., among subjects showing the least improvement. In a longitudinal case study
(Kellner et al., 2002), morning salivary RIA cortisol levels did not show significant decline
until the third month following trauma and only began to rise as clinical symptoms showed
initial indications of sustained improvement, This, and the results of the current investigation,
suggest that cortisol levels may continue to decline as PTSD becomes more chronic or
treatment-resistant.
By adding an evaluation of cortisol metabolites to the neuroendocrine assessment in the current
study, it was possible to identify 5α–reductase activity as a putative predictor that differentiated
responders from non-responders at the pre-treatment evaluation. Changes in the activity of
glucocorticoid metabolic enzymes, and in particular, 5α-reductase, have been observed in
association with extreme stress (Sánchez et al., 2008). We infer that this reflects the 5α-
reductase type 1 isozyme, highly expressed in liver and brain in both genders, since the other
isoform, 5α-reductase type 2 is largely confined to male secondary sexual structures. 5α-
reductase activity is increased in obesity (Livingstone et al., 2000), but lower activity was seen
in the treatment-resistant group which had the higher BMI, suggesting that this is not the cause
of the differences observed. Diminished 5α-reductase activity has been associated with
cardiovascular risk, the development of metabolic syndrome, as well as other health related
risk factors associated with trauma exposure and PTSD (Jakovljevic et al., 2006; Vieweg et
al., 2006; Violanti et al., 2006). It is possible that changes in 5α–reductase occurred early in
response to the trauma of the 9/11 attacks. Conversely, insofar as lifespan levels of 5α-reductase
have also been associated with perinatal (developmental) 'programming,' in rodents, it is
plausible that the observed differences between responders and non-responders constitute a
pretraumatic risk factor that also increased the risk for the development of PTSD, or more
refractory PTSD, following 9/11 (Melcangi et al., 1998).
At pre-treatment, indices of diminished 5α-reductase activity and associated hormonal
measures were correlated with avoidance. According to psychological models of PTSD,
chronic PTSD results from behavioral and cognitive avoidance of traumatic reminders. The
design of the current study, however, does not speak to the origin of lower 5α-reductase in
PTSD. The current findings imply that avoidance may be underpinned by altered cortisol
metabolism, specifically by lowered 5α-reductase, which itself may be a lifelong trait.
Interestingly, there is an emerging behavioral literature to support enhanced fear, and anxiety-
like behaviors in response to experimentally induced 5α–reductase inhibition (Frye et al.,
2004; Kita et al., 2008; Mann 2006). Mice subjected to prolonged social isolation develop
enhanced contextual fear, impaired fear extinction, and emotional hyper-reactivity in temporal
association with diminished 5α-reductase activity in medial prefrontal cortex, hippocampus
and basolateral amygdala (Agís-Balboa et al., 2007). Whether, in the present study, lower 5α-
reductase preceded 9/11, was a consequence of exposure, or of the development of PTSD, the
finding was associated with PTSD symptom severity and maintenance.
The activities of glucocorticoid metabolic enzymes alter the effective half-life of cortisol and
may accordingly influence the HPA axis (Andrew at al., 1998). In the current study, the
activities of 5α–reductase, 5β-reductase and of 11β-HSDs remained stable, even as the overall
rate of cortisol production declined. These findings suggest that the factors involved in
regulating enzyme activity in PTSD may be distinct from those determining overall cortisol
production in the adrenal gland.
In view of the fact that cortisol levels have not been found to change in response to
pharmacological intervention in PTSD (Tucker et al., 2004a, 2004b), it is appropriate to
consider whether alterations in cortisol levels may reflect alterations in the psychological
processes that are altered by psychotherapy – e.g., cognitive appraisal and coping styles. This
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would be consistent with the suggestion of Mason et al. (2001) that fluctuations in urinary
cortisol excretion over time in combat veterans are mediated by psychological processes and
transient stressors. That cortisol treatment may be effective in alleviating symptoms of PTSD
(Aerni et al., 2004), or even in preventing the onset of the disorder (Shelling et al., 2006), is
consistent with this proposition.
An interpretive challenge for this study is the absence of a non-exposed control group, or a
comparably exposed group that did not develop PTSD. All persons studied demonstrated
significant enough PTSD symptoms to warrant treatment. Thus, while conclusions about
biological predictors and correlates of recovery can be made, the design does not permit
inferences regarding measures associated with trauma exposure or resistance to PTSD.
Moreover, as subjects were studied within a year of exposure to 9/11, it is likely that at least
some of the observed reductions in symptom severity may represent spontaneous recovery
rather than treatment response (Kessler et al., 1995).
The study has several limitations. First, the subject number is relatively modest. This limitation
is partially offset by having three repeated observations over time with no missing data. A
related problem concerns the representativeness of the sample. As stated above, the 28 subjects
reported here consist of a subset of a larger group of 44 subjects who completed treatment,
who themselves are a subset of an even larger group randomized to psychotherapy after meeting
specific inclusion/exclusion criteria. Thus the degree to which persons studied here represent
all treatment seekers in the immediate months post-trauma is unclear. This problem is
magnified by the fact that those who sought treatment in the first few months after 9/11 were
not typical of the larger community with 9/11-related PTSD (Boscarino et al., 2004).
Nonetheless, subjects enrolled in treatment who were not included in the present analyses did
not differ from the 28 included subjects on any clinical or biological variable of interest at
initial evaluation. An additional weakness of the study is the absence of information on cigarette
smoking. Tobacco use elevates cortisol levels (Steptoe & Ussher, 2006), and may interact with
posttraumatic major depression to affect HPA axis parameters (Olff et al., 2006b). Although
the distribution of depression did not differ between responder and non-responder groups,
tobacco use may have been a relevant covariate and should be examined in future studies.
Finally, in interpreting the significance of the study it is important to note that the criterion
used to differentiate responders from non-responders was extremely conservative, and
designed to produce a group of persons who not only no longer met criteria for PTSD post-
treatment, but had achieved complete clinical remission (Schnurr et al., 2007). The intervention
literature generally employs less stringent criteria for segregating responders from non-
responders to examine treatment efficacy. In the present study, however, a psychotherapeutic
intervention was exploited to manipulate symptoms to the greatest extent possible so that
biological correlates of treatment response and symptoms could be evaluated.
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Figure 1. Summary of metabolic pathways
11β-HSD is 11β-hydroxysteroid dehydrogenase. Type 1 oxidizes cortisol to cortisone; Type 2
reduces inert cortisone to cortisol. 5α- and 5β -reductase are the rate limiting enzymes in the
conversions of cortisol to 5α-THF and 5β-THF, respectively. 5β-reductase is also rate limiting
in the conversion of cortisone to THE.
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Figure 2. Percent change in means of free cortisol (F) and metabolites from pre-treatment to follow-
up for treatment non-responders and responders
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Table 3
Relationships of 5α-reductase and related glucocorticoid metabolites to self-rated PTSD symptoms at pre-
treatment and follow-up
a. Pre-Treatment PSSR:Intrusive Avoidance Hyperarousal Total score
ra, p r, p r, p r, p
Pre-treatment biology:
  5α-THF .024, nsb −.510, .009 −.092, ns −.339, (.098)
  Total glucocorticoids −.035, ns −.473, .017 −.087, ns −.333, ns
  5α-reductase −.035, ns −.444, .026 −.221, ns −.335, ns
b. Follow-Up PSSR: Intrusive Avoidance Hyperarousal Total score
ra, p r, p r, p r, p
Follow-up biology:
  5α-THF −.473, .023 −.581, .004 −.547, .007 −.582, .004
  Total glucocorticoids −.651, .001 −.669, <.0005 −.682, <.0005 −.719, <.0005
  5α-reductase −.433, .039 −.461, .027 −.501, .015 −.501, .015
a
Partial correlations, controlling for age, gender and BMI
b
ns: p≥.10
5α-THF=5α-tetrahyrdocortisol (GCMS); Total glucocorticoids=sum of UFF, UFE, 5α-THF, 5β-THF and THE; 5α-reductase=Inferred from 5α-THF/F
ratio. Bonferroni considerations applied to metabolites and enzyme measures independently. Bold typeface indicates results meeting Bonferroni criteria
for statistical significance.
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